United Therapeutics Corp 2024 SR
The report highlights United Therapeutics' progress as a public benefit corporation in 2023, focusing on its mission to expand organ transplant availability and develop rare disease therapies. Key achievements include serving over 14,500 patients, reaching record revenue with 20% growth, and completing acquisitions of Miromatrix and IVIVA. The company advanced its organ manufacturing pipeline with successful xenotransplantation procedures and bioengineered organ clinical trial clearance. Environmental efforts featured securing LEED Gold certification for a new warehouse and maintaining significant onsite solar capacity. Socially, the company maintained a low 5% voluntary turnover rate and high employee engagement scores.
Company: United Therapeutics Corp
Sector: Health Care
Country: United States
Year: 2024
Type: SR
Pages: 79
United Therapeutics Corp
Corporate Responsibility And Public Benefit Report
The report highlights United Therapeutics' progress as a public benefit corporation in 2023, focusing on its mission to expand organ transplant availability and develop rare disease therapies. Key achievements include serving over 14,500 patients, reaching record revenue with 20% growth, and completing acquisitions of Miromatrix and IVIVA. The company advanced its organ manufacturing pipeline with successful xenotransplantation procedures and bioengineered organ clinical trial clearance. Environmental efforts featured securing LEED Gold certification for a new warehouse and maintaining significant onsite solar capacity. Socially, the company maintained a low 5% voluntary turnover rate and high employee engagement scores.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Sep 12, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees